Eli Lilly's Ebglyss Emerges as New Option for Patients Struggling with Dupixent Treatment
Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...
The Pharma Letter6h
Lilly's Ebglyss demonstrated meaningful improvement in eczema
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...
FiercePharma6h
J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups
Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...
Lilly's Ebglyss shown to be effective in former Dupixent users
Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...
Eli Lilly presents new Ebglyss data at FCD Conference
New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...
Swissinfo20h
News today from Switzerland
This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...